Impact of prior invasive aspergillosis on outcome in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplant

References

• Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002;100:4358–4366.
   PubMed Web of Science ®Google Scholar
• Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997;175:1459–1466.
   PubMed Web of Science ®Google Scholar
• Martino R, Lopez R, Sureda A, Brunet S, Domingo-Albós A. Risk of reactivation of a recent invasive fungal infection in patients with hematological malignancies undergoing further intensive chemo-radiotherapy. A single-center experience and review of the literature. Haematologica 1997;82:297–304.
   Google Scholar
• Richard C, Romón I, Baro J, et al Invasive pulmonary aspergillosis prior to BMT in acute leukemia patients does not predict a poor outcome. Bone Marrow Transplant 1993;12:237–241.
   PubMed Web of Science ®Google Scholar
• Fukuda T, Boeckh M, Guthrie KA, et al Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center. Biol Blood Marrow Transplant 2004;10:494–503.
   PubMed Web of Science ®Google Scholar
• Martino R, Parody R, Fukuda T, et al Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: a retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 2006;108:2928–2936.
   PubMed Web of Science ®Google Scholar
• Safdar A, Rodriguez GH, Mihu CN, et al Infections in non-myeloablative hematopoietic stem cell transplantation patients with lymphoid malignancies: spectrum of infections, predictors of outcome and proposed guidelines for fungal infection prevention. Bone Marrow Transplant 2010;45:339–347.
   PubMed Web of Science ®Google Scholar
• De Pauw B, Walsh TJ, Donnelly JP, et al Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group; Clin Infect Dis 2008;46:1813–1821.
   PubMed Web of Science ®Google Scholar
• Subirà M, Martino R, Rovira M, et al Clinical applicability of the new EORTC/MSG classification for invasive pulmonary aspergillosis in patients with hematological malignancies and autopsy-confirmed invasive aspergillosis. Ann Hematol 2003;82:80–82.
   PubMed Web of Science ®Google Scholar
• Ascioglu S, Rex JH, de Pauw B, et al Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis;34:7–14.
   PubMed Web of Science ®Google Scholar
• Mohty M, Bay JO, Faucher C, et al Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood 2003;102:470–476.
   PubMed Web of Science ®Google Scholar
• El-Cheikh J, Faucher C, Mohty M, et al High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 2007;39:301–306.
   PubMed Web of Science ®Google Scholar
• Slavin MA, Osborne B, Adams R, et al Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation–a prospective, randomized, double-blind study. J Infect Dis 1995;171:1545–1552.
   PubMed Web of Science ®Google Scholar
• Marr KA, Seidel K, Slavin MA, et al Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000;96:2055–2061.
   PubMed Web of Science ®Google Scholar
• Marr KA, Balajee SA, McLaughlin L, Tabouret M, Bentsen C, Walsh TJ. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 2004;190:641–649.
   PubMed Web of Science ®Google Scholar
• Musher B, Fredricks D, Leisenring W, Balajee SA, Smith C, Marr KA. Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. J Clin Microbiol 2004;42:5517–5522.
   PubMed Web of Science ®Google Scholar
• Ribaud P, Chastang C, Latge JP, et al Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. Clin Infect Dis 1999;28:322–330.
   PubMed Web of Science ®Google Scholar
• Harrel FE Jr. Regression modeling strategies. Springer series in statistics. Berlin: Springer; 2001.
   Google Scholar
• Baddley JW, Stroud TP, Salzman D, Pappas PG. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001;32:1319–1324.
   PubMed Web of Science ®Google Scholar
• Fukuda T, Boeckh M, Carter RA, et al Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003;102:827–833.
   PubMed Web of Science ®Google Scholar
• Offner F, Cordonnier C, Ljungman P, et al Impact of previous aspergillosis on the outcome of bone marrow transplantation. Clin Infect Dis 1998;26:1098–1103.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic co morbidity in longitudinal studies: development and validation. J Chron Dis 1987;40:373–383.
   PubMedGoogle Scholar
• Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004;39:797–802.
   PubMed Web of Science ®Google Scholar
• Singh N, Limaye AP, Forrest G, et al Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006;81:320–326.
   PubMed Web of Science ®Google Scholar
• Safdar A, Rodriguez GH, De Lima MJ, et al Infections in 100 cord blood transplantations: spectrum of early and late post transplant infections in adult and pediatric patients 1996–2005. Medicine (Baltimore) 2007;86:324–333.
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Maury S, Pautas C, et al Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transplant 2004;33:943–948.
   PubMed Web of Science ®Google Scholar
• De Fabritiis P, Spagnoli A, Di Bartolomeo P, et al Efficacy of caspofungin as secondary prophylaxis in patients undergoing allogeneic stem cell transplantation with prior pulmonary and/or systemic fungal infection. Bone Marrow Transplant 2007;40:245–249.
   PubMed Web of Science ®Google Scholar
• Krüger WH, Rüssmann B, de Wit M, et al Haemopoietic cell transplantation of patients with a history of deep or invasive fungal infection during prophylaxis with liposomal amphotericin B. Acta Haematol 2005;113:104–108.
   PubMed Web of Science ®Google Scholar
• Sipsas NV, Kontoyiannis DP. Clinical issues regarding relapsing aspergillosis and the efficacy of secondary antifungal prophylaxis in patients with hematological malignancies. Clin Infect Dis 2006;42:1584–1591.
   PubMed Web of Science ®Google Scholar
• Mohty M, Jacot W, Faucher C, et al Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen. Leukemia 2003;17: 2168–2177.
   PubMed Web of Science ®Google Scholar
• Balloy V, Huerre M, Latge JP, Chignard M. Differences in patterns of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis. Infect Immun 2005;73:494–503.
   PubMed Web of Science ®Google Scholar
• Diaconescu R, Flowers CR, Storer B, et al Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 2004;104:1550–1558.
   PubMed Web of Science ®Google Scholar